Evaluation of 90Y-DTPA and 90Y-DOTA for potential application in intra-vascular radionuclide therapy

Y-90-1,4,7,10-tetraazacyclododecane tetraacetic acid (Y-90-DOTA) and Y-90-diethylene triamine pentaacetic acid (Y-90- DTPA) complexes were studied for possible use in intra-vascular radionuclide therapy (IVRNT). Y-90 was obtained from a Sr-90-Y-90 generator based on supported liquid membrane technique. The Y-90-DOTA and Y-90-DTPA complexes were prepared under optimised conditions. Bio-distribution of the complexes in Swiss mice showed that nearly 90% of Y-90 complexes of both the ligands were excreted via urine within 1 h post-injection with negligible localisation in vital organs. Probenecid inhibition studies showed that both complexes are excreted by glomerular filtration. The predominant and quick excretion of Y-90-DOTA and Y-90-DTPA through the kidneys suggest that both these complexes could be explored for use in IVRNT. (C) 2002 Elsevier Science Ltd. All rights reserved.